• 基本信息
    导师姓名： 庄光磊 学科代码： 100214
    性别： 男 学科名称： 肿瘤学
    培养单位： 附属仁济医院 三级学科
    导师类型： 博士生导师 专业领域名称：
    联系方式： zhuanglab@163.com https://www.x-mol.com/groups/zhuanglab 专业领域代码：
    邮编： 邮箱地址： zhuangguanglei@163.com
  • 研究方向 (点击浏览详细信息)
  • 社会任职
     
    中国生理学会基质生物学专业委员会委员
    上海市妇科肿瘤重点实验室副主任
  • 科研项目
    项目编号项目名称课题来源起止年月批准经费承担职责
    82373351肺癌中抑制PIKfyve下调YY1促进靶向治疗敏感性的作用与机制国家自然科学基金面上项目 2024-01~2027-12 49万元  课题负责人
    82172596靶向转录延伸调控激酶CDK12/CDK13的新型共价键抑制剂治疗卵巢癌的作用与机制国家自然科学基金面上项目 2022-01~2025-12 55万元  课题负责人
    81922047肿瘤动态演进与靶向治疗国家自然科学基金优青项目 2020-01~2022-12 120万元  课题负责人
    81672714去泛素化酶USP13促进MCL1稳定性和肿瘤发展的机制研究国家自然科学基金面上项目 2017-01~2020-12 58万元  课题负责人
    16QA1403600肺癌的分子诊断和精准治疗研究上海市青年科技启明星计划 2016-04~2019-03 40万元  课题负责人
    2015卵巢癌表观遗传治疗研究上海高校特聘教授 2015-07~2018-06 100万元  课题负责人
    81472537特异micoRNAs与Lin28B的相互调控促进黑色素瘤发展的机制研究国家自然科学基金面上项目 2015-01~2018-12 78万元  课题负责人
  • 学术论文
    作者论文标题期刊名出版年卷期页码
    Zang J, Zhang R, Jin D, Xie F, Shahatiaili A, Wu G, Zhang Y, Zhao Z, Du P, Jia S, Chen H,  Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial  J Pathol  2023  261(2):198-209. 
    Wang J, Zhou S, Cheng Y, Cheng L, Qin Y, Zhang Z, Bi A, Xiang H, He X, Tian X, Liu W, Zhang J, Peng C, Zhu Z, Huang M, Li Y,, Tan L  Selective covalent targeting of pyruvate kinase M2 using arsenous warheads  J Med Chem  2023  66(4):2608-2621. 
    Shi K, Lu H, Zhang Z, Fu Y, Wu J, Zhou S, Ma P, Ye K, Zhang S, Shi H, Shi W, Cai MC, Zhao X, Yu Z, Tang J,  Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancer  Cell Death Differ  2023  30(1):195-207. 
    Zhang R, Zang J, Jin D, Xie F, Shahatiaili A, Wu G, Zhang L, Wang L, Zhang Y, Zhao Z, Du P, Jia S, Fan J,, Chen H  Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer  Clin Cancer Res  2023  CCR-23-0513. 
    Long X, Lu H, Cai MC, Zang J, Zhang Z, Wu J, Liu X, Cheng L, Cheng J, Cheung LWT, Shen Z, Zhou Y, Di W,, Yin X  APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis  Br J Cancer  2023  128(11):2054-2062. 
    Tan L, Shan H, Han C, Zhang Z, Shen J, Zhang X, Xiang H, Lu K, Qi C, Li Y,, Chen G, Tan L  Discovery of potent OTUB1/USP8 dual inhibitors targeting proteostasis in non-small-cell lung cancer  J Med Chem  2022  65(20):13645-13659. 
    Lin L, Shi K, Zhou S, Cai MC, Zhang C, Sun Y, Zang J, Cheng L, Ye K, Ma P, Shen P, Zhang M, Cheng Y, Qi C, Li Y, Yin X, Zheng Y, Tan L,, Zang R  SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer  Oncogene  2022  41(12):1767-1779. 
    Cheng L, Zhou S, Zhou S, Shi K, Cheng Y, Cai MC, Ye K, Lin L, Zhang Z, Jia C, Xiang H, Zang J, Zhang M, Yin X, Li Y, Di W,, Tan L  Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer  Cancer Res  2022  82(19):3588-3602. 
    Ren F, Xie M, Gao J, Wu C, Xu Y, Zang X, Ma X, Deng H, Song J, Huang A, Pang L, Qian J, Yu Z,, Liu S, Pan L, Xue X  Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors  Cancer Med  2022  11(15):2969-2977. 
    Meng X, Qian X, Ding X, Wang W, Yin X,, Zeng W  Eosinophils regulate intra-adipose axonal plasticity  Proc Natl Acad Sci U S A  2022  119(3):e2112281119. 
    Sun Y, Zhang Z, Zhang K, Liu Y, Shen P, Cai MC, Jia C, Wang W, Gu Z, Ma P, Lu H, Guan L, Di W,, Yin X  Epigenetic heterogeneity promotes acquired resistance to BET bromodomain inhibition in ovarian cancer  Am J Cancer Res  2021  11(6):3021-3038. 
    Zang J, Ye K, Fei Y, Zhang R, Chen H,  Immunotherapy in the treatment of urothelial bladder cancer: insights from single-cell analysis  Front Oncol  2021  11:696716. 
    Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J, Ren F, Pang L, Qian J, Yu Z, Wan S, Chen Y, Pan L,, Liu S, Xue X  Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis  BMC Cancer  2021  21(1):634. 
    Zhang Y, Yu M, Jing Y, Cheng J, Zhang C, Cheng L, Lu H, Cai MC, Wu J, Wang W, Lou W, Qiu L, Tan L, Lu H, Yin X,, Di W  Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer  Br J Cancer  2021  124(2):414-424. 
    Jia C, Zhang Z, Tang J, Cai MC, Zang J, Shi K, Sun Y, Wu J, Shi H, Shi W, Ma P, Zhao X, Yu Z, Fu Y,  Epithelial-mesenchymal transition induces GSDME transcriptional activation for inflammatory pyroptosis  Front Cell Dev Biol  2021  9:781365. 
    Yin X, Bi R, Ma P, Zhang S, Zhang Y, Sun Y, Zhang Y, Jing Y, Yu M, Wang W, Tan L, Di W,, Cai MC  Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma  J Med Genet  2020  57(9):605-609. 
    Cai MC, Zhao X, Cao M, Ma P, Chen M, Wu J, Jia C, He C, Fu Y, Tan L, Xue X, Yu Z,  T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment  J Pathol  2020  251(2):147-159. 
    Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB,, Xue X, Han L  Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy  Nat Commun  2020  11(1):4946. 
    Jing Y, Zhang Y, Zhu H, Zhang K, Cai MC, Ma P, Shen P, Zhang Z, Shao M, Wang J, Yu M, Yin X, Zhang M, Hu Y, Chen D, Di W, Wang X,  Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer  Oncogene  2019  38(16):3047-3060. 
    Shi K, Yin X, Cai MC, Yan Y, Jia C, Ma P, Zhang S, Zhang Z, Gu Z, Zhang M, Di W,  PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors  Elife  2019  8:e44306. 
    Cai MC, Chen M, Ma P, Wu J, Lu H, Zhang S, Liu J, Zhao X,, Yu Z, Fu Y  Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer  Int J Cancer  2019  144(4):788-801. 
    Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, Wang X, Di W,  Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors  Nat Commun  2018  9(1):215. 
    Shen P, Jing Y, Zhang R, Cai MC, Ma P, Chen H,  Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics  Oncogene  2018  37(22):3039-3044. 
    Lu H, Zhang S, Wu J, Chen M, Cai MC, Fu Y, Li W, Wang J, Zhao X, Yu Z, Ma P,  Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death  Clin Cancer Res  2018  24(23):6066-6077. 
    Jing Y, Zhang R, Ma P, Cai MC,, Chen H  Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate  J Pathol.  2018  244(1):5-10. 
    Zhang M,, Sun X, Shen Y, Wang W, Li Q, Di W  TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer  Diagn Pathol  2017  12(1):16. 
    Ma P, Fu Y, Cai MC, Yan Y, Jing Y, Zhang S, Chen M, Wu J, Shen Y, Zhu L, Chen HZ, Gao WQ, Wang M, Gu Z, Bivona TG, Zhao X,  Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer  Nat Commun  2017  8(1):823. 
    Zhang Z, Peng H, Wang X, Yin X, Ma P, Jing Y, Cai MC, Liu J, Zhang M, Zhang S, Shi K, Gao WQ, Di W,  Preclinical efficacy and molecular mechanism of targeting CDK7-dependent transcriptional addiction in ovarian cancer  Mol Cancer Ther  2017  16(9):1739-1750. 
    Yin X, Jing Y, Cai MC, Ma P, Zhang Y, Xu C, Zhang M, Di W,  Clonality, heterogeneity, and evolution of synchronous bilateral ovarian cancer  Cancer Res  2017  77(23):6551-6561. 
    Zhu HH,, Gao WQ   A candidate gastric stem/progenitor cell marker revealed by genome-wide analysis  J Pathol  2016  238(1):3-6. 
    Ma P, Fu Y, Chen M, Jing Y, Wu J, Li K, Shen Y, Gao JX, Wang M, Zhao X,  Adaptive and acquired resistance to EGFR inhibitors converge on the MAPK pathway  Theranostics  2016  6(8):1232-43. 
    Jing Y, Zhang Z, Ma P, An S, Shen Y, Zhu L,  Concomitant BET and MAPK blockade for effective treatment of ovarian cancer  Oncotarget  2016  7(3):2545-54.  
    Yin X, Wang X, Shen B, Jing Y, Li Q, Cai MC, Gu Z, Yang Q, Zhang Z, Liu J, Li H, Di W,  A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis  Sci Rep  2016  6:31079. 
    Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, Gu Z, Gao WQ,  BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1  Theranostics  2016  6(2):219-30. 
    Zhang S, Jing Y, Zhang M, Zhang Z, Ma P, Peng H, Shi K, Gao WQ,  Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer  Sci Rep  2015  5:16066. 
    Zhang Z, Zhang S, Ma P, Jing Y, Peng H, Gao WQ,  Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit  Carcinogenesis  2015  36(9):937-45. 
    Li X, Liu Y, Chen W, Fang Y, Xu H, Zhu HH, Chu M, Li W,, Gao WQ  TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer  Oncotarget  2014  5(19):9498-513. 
    Brauer MJ,, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RN, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C  Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies  Clin Cancer Res  2013  19(13):3681-92. 
    , Yu K, Jiang Z, Chung AS, Yao J, Ha C, Toy K, Soriano R, Haley B, Blackwood E, Sampath D, Bais C, Lill JR, Ferrara N  Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases  Sci Signal  2013  6(271):ra25. 
    , Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D, Ferrara N  Tumor-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway  EMBO J  2012  31(17):3513-23. 
    , Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, Shyr Y, Lin L, Carbone DP, Brantley-Sieders DM, Chen J  Effects of cancer-associated EPHA3 mutations on lung cancer  J Natl Cancer Inst  2012  104(15):1183-98. 
    , Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J  Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy  Cancer Res  2010  70(1):299-308. 
    Brantley-Sieders DM,, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling  J Clin Invest  2008  118(1):64-78. 
    , Hunter S, Hwang Y, Chen J  Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation  J Biol Chem  2007  282(4):2683-94.